1 / 14

Monitoring HPV vaccine impact in Connecticut

Monitoring HPV vaccine impact in Connecticut. Linda Niccolai, PhD Yale School of Public Health 2008 National STD Prevention Conference Chicago, IL. Overview. Multi-site, CDC-funded project to monitor HPV vaccine impact through laboratory-based surveillance of cervical cancer precursors

verda
Télécharger la présentation

Monitoring HPV vaccine impact in Connecticut

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Monitoring HPV vaccine impact in Connecticut Linda Niccolai, PhD Yale School of Public Health 2008 National STD Prevention Conference Chicago, IL

  2. Overview • Multi-site, CDC-funded project to monitor HPV vaccine impact through laboratory-based surveillance of cervical cancer precursors • Adding cervical cancer precursors to list of reportable diseases

  3. It Takes a Village • CT Emerging Infections Program (EIP) • James Meek MPH, Ruthanne Marcus MPH, Pamela Julian MPH, Robert Heimer PhD • CT Department of Public Health • James Hadler MD MPH, Lynn Sosa MD, Matt Cartter MD MPH, Maria Andrews MPH • Yale School of Public Health • Linda Niccolai PhD, Daina Barauskas MPH(c) • Other local partners • For example: Hospital and commercial pathology laboratories • National partners • For example: CDC, other EIP sites

  4. Purpose of EIP project • Goal • To develop and implement laboratory-based reporting of cervical intraepithelial neoplasia grades 2 and 3 (CIN 2/3) and adenocarcinoma in situ (AIS) • Specific Aims • Monitor trends in CIN 2/3 & AIS diagnoses • Monitor trends in HPV type-specific CIN 2/3 & AIS • Estimate vaccination patterns and screening histories among cases

  5. Overview of EIP project • Currently funded for 2 years at 4 EIP sites • CT, NY, TN, CA • Defined catchment areas • Typically county level • Laboratory-based surveillance for CIN 2/3 & AIS • All cases reported using 1-page case report form • Enhanced surveillance for more detailed information on a representative subset including clinical history (vaccine, screening) and specimen collection (typing)

  6. Protocol Labs send case report form to Yale EIP Resident of New Haven Co. Resident outside New Haven Co. Verify diagnosis is reportable Verify diagnosis is reportable Enter into state surveillance database Enter into state surveillance database Enhanced surveillance on subset age 18-39 • Ask labs to send biopsy specimens • Collect additional clinical information

  7. Conducting a provider survey • Purpose • To identify all pathology labs that process cervical biopsy specimens for New Haven Co. residents • Methods • Telephone survey of providers likely to conduct cervical biopsies including OB/GYN, IM, FP, others • Results • We identified 11 pathology laboratories • 8 hospital-based, 3 commercial • Largest labs include Yale, Quest

  8. Approach to working with pathology labs • Initial contact • Explain purpose of project • Follow-up • Meet to discuss implementation • Key points of partnership • Flexibility and ease • Importance of and benefit to labs • Public health significance

  9. Background on disease reporting in CT • All states have lists of reportable diseases that are considered to have “public health importance” • Needs to be flexible to conduct surveillance for new conditions when they arise (e.g. Lyme disease, HIV), yet process of approval by legislature cumbersome, political and time consuming • In 1985, Connecticut General Statutes Section 19a-2a that mandates disease reporting was amended to include, “Annually issue a list of reportable diseases and reportable laboratory findings and amend such list as he (Commissioner of Public Health) deems necessary”. • Law made CT unique at the time in flexibility to conduct surveillance and when to begin

  10. Process • State Epidemiologist selects and convenes an Advisory Committee to make recommendations to the Commissioner of Public Health • Advisory Committee composed representatives from groups that must do the work of reporting (e.g. lab directors, hospital epidemiologists) and other stake holders (public health officials) • Meet annually to discuss, vote, and make recommendations (majority) to Commissioner • Commissioner makes a final decision and approves list before Jan 1 each year • Lists disseminated

  11. Making CIN 2/3 & AIS reportable • Rationale • Evaluate vaccination efforts • Gain more information to guide vaccination programs and strategies • Issues raised by committee • Overlap with tumor registry • Specimen collection – feasibility and liability • Patient confidentiality • Outcome • Recommended to and accepted by Commissioner

  12. Contact us! Linda Niccolai Yale School of Public Health (203) 785-7834 Linda.Niccolai@yale.edu

  13. What to report? • To direct case-specific PH intervention (e.g. treatment, exposure) • To plan or evaluate PH programs to prevent disease when public health intervention is available • To gain more information that may be necessary before prevention can be implemented • Points 2 & 3 are particularly salient for vaccines • E.g. varicella, pneumococcal disease

More Related